

Supplemental Table 3. Plasma emtricitabine (FTC) pharmacokinetics

	C_{tau} (ng/mL)	C_{max} (ng/mL)	T_{max} (hrs)	AUC_{tau} (ng*hr/mL)	T_{1/2} (hrs)
OVERALL	92.1 (83.1, 102.1)	1924 (1748, 2118)	1.6 (1.4, 1.8)	12,150 (11,344, 13,012)	6.6 (6.2, 7.0)
Transgender women (N=26)	86.9 (73.7, 102.5)	1729 (1530, 1954)	1.6 (1.3, 2.0)	11,071 (10,019, 12,233)	6.7 (6.0, 7.5)
Transgender men (N=24)	98.1 (86.4, 111.4)	2161 (1870, 2497)	1.6 (1.4, 1.8)	13,437 (12,385, 14,579)	6.4 (6.0, 6.8)
TM vs. TW, GMR (95% CI)	1.13 (0.92, 1.39)	1.25 (1.04, 1.50)	0.98 (0.76, 1.25)	1.21 (1.07, 1.38)	0.95 (0.83, 1.09)
P-value	0.242	0.019	0.867	0.004	0.424
HISTORICAL CONTROLS					
Shieh, et al. Median (IQR)	88 (64, 102)	2284 (1415, 2889)	-	12,698 (11,114, 13,683)	-
Cirincione, et al. GM (90% CI)	-	1660 (1550, 1790)	2.9 (2.4, 3.6)	10,640 (10,180, 11,110)	10.6 (10.1, 11.0)
Cell-PrEP ^a Mean (95% CI)	-	-	-	10,344 (9216, 11,472)	11.0 (7.7, 14)

All values expressed as geometric mean (95% CI), unless otherwise stated. ^a AUC calculated as C_{ss}*24 hrs.